Sociedad Americana de Hirudoterapia

Leech therapy for postoperative pain and swelling after knee arthroscopy: a randomized controlled trial

Bishaw AM, El-Sayed M, Hassan H, Ibrahim M (2020) · Egyptian Rheumatology and Rehabilitation · n=60

Detalle de evidencia de RCTReferencia del ensayo
GRADE bajaCohorte / serie de casos

Perfil del estudio

Diseño
single-center, open-label, randomized controlled trial (Cairo)
Tamaño de la muestra (n)
60
Intervención
Single session of 3-4 Hirudo medicinalis leeches at the postoperative knee, applied 24 hours post-arthroscopy
Comparador
Standard analgesia: oral diclofenac 75mg twice daily + cold pack for 5 days
Punto final primario
Pain on 100mm VAS at day 5
Resultado primario
VAS pain reduction 36.4mm in leech vs 22.8mm in standard care at day 5 (between-group difference 13.6mm, p=0.008); knee circumference (swelling) decreased 1.8cm vs 0.7cm
Effect size (Cohen's d)
0.69
Duración del seguimiento
4 weeks

Hallazgos clave

  • First RCT of leech therapy in immediate postoperative period after orthopedic surgery
  • Significant reduction in both pain and objectively measured knee swelling
  • Lower opioid rescue use in leech arm (1.4 vs 3.2 doses over 5 days)
  • Earlier return to weight-bearing in leech arm (day 3.2 vs day 4.8)
  • No surgical-site infections in either arm

Limitaciones

  • Single center, Egypt
  • Open-label
  • Excluded patients on chronic anticoagulation
  • 4-week follow-up too short to address late outcomes (rehabilitation, return to sport)
  • Variable arthroscopic procedures (meniscectomy, ACL, microfracture) — heterogeneous primary surgery

Implicaciones clínicas

Bishaw 2020 is the only RCT for hirudotherapy in the immediate postoperative orthopedic setting. The pain and swelling reductions plus lower opioid rescue use are clinically meaningful given the current opioid-sparing imperative. For orthopedic centers willing to manage the operational complexity (leech storage, biohazard handling) in a postoperative ward, this trial supports adjunctive use after knee arthroscopy.

Este sitio web proporciona información educativa y no constituye consejo médico, diagnóstico ni recomendaciones de tratamiento. La terapia con sanguijuelas medicinales conlleva riesgos clínicamente significativos y debe ser realizada únicamente por profesionales calificados bajo protocolos aprobados institucionalmente. La autorización 510(k) de la FDA para sanguijuelas medicinales se limita a indicaciones específicas; las discusiones sobre uso investigativo y fuera de indicación se señalan correspondientemente. Para orientación médica específica, consulte a un profesional de salud calificado.